Clinical trial design and evidence-based outcomes in the study of liver diseases

Journal of Hepatology

Volumn 50, Issue 4, 2009, Pages 817-826

  Croswell, Jennifer M ^a   Kramer, Barnett S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Clinical design; Evidenced based outcomes; Surrogate endpoints

Indexed keywords

CLINICAL STUDY; EVIDENCE BASED PRACTICE; HEALTH HAZARD; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; SIGNAL NOISE RATIO; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; LIVER DISEASES; RESEARCH DESIGN;

EID: 61849129362     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.01.005     Document Type: Review

References (21)

1. Hume D. Of Miracles. In: An Enquiry Concerning Human understanding. Whitefish: Kessinger Publishing; 2004.
2. Ludmerer KM. Time to heal: American medical education from the turn of the century to the era of managed care. New York: Oxford University Press; 1999.
3. Harris R.P., Helfand M., Woolf S.H., Lohr K.N., Mulrow C.D., Teutsch S.M., et al. Methods work group, third US preventive services task force. Current methods of the US preventive services task force: a review of the process. Am J Prev Med 20 (2001) 21s-35s
4. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
5. Harmanci O., Buyukasik Y., and Bayraktar Y. Successful plasma exchange treatment in hemolytic crisis of Wilson's disease preventing liver transplantation. Dig Dis Sci 51 (2006) 1230
6. Riley T.R., and Taheri M.R. Long-term treatment with the combination of amantadine and ribavirin in hepatitis C non-responders. A case series. Dig Dis Sci 52 (2007) 3418-3422
7. Ederer F. Why do we need controls? Why do we need to randomize?. Am J Opthalmol 79 (1975) 758
8. Denis J., Opolon P., Nusinovici V., Granger A., and Darnis F. Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane. Gut 19 (1978) 787-793
9. MacMahon B., Yen S., Trichopoulos D., Warren K., and Nardi G. Coffee and cancer of the pancreas. N Engl J Med 304 (1981) 630-633
10. Yen S., Hsieh C.C., and MacMahon B. Consumption of alcohol and tobacco and other risk factors for pancreatitis. Am J Epidemiol 116 (1982) 407-414
11. Hsieh C.C., MacMahon B., Yen S., Trichopoulos D., Warren K., and Nardi G. Coffee and pancreatic cancer (Chapter 2). N Engl J Med 315 (1986) 587-589
12. Ransohoff D.F. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 97 (2005) 315-319
13. Fleming T.R., and DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 125 (1996) 605-613
14. Levin B., Lieberman D.A., McFarland B., Smith R.A., Brooks D., Andrews K.S., et al. American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58 (2008) 130-160
15. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
16. Feynman R. Cargo Cult Science. In: Surely You're Joking, Mr. Feynman! New York: W.W. Norton, Inc.;1985.
17. Levin B. Potential pitfalls in the use of surrogate endpoints in colorectal adenoma chemoprevention. J Natl Cancer Inst 95 (2003) 697-699
18. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
19. Beresford S.A., Johnson K.C., Ritenbaugh C., Lasser N.L., Snetselaar L.G., Black H.R., et al. Low-fat dietary pattern and risk of colorectal cancer: the women's health initiative randomized controlled dietary modification trial. JAMA 295 (2006) 643-654
20. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
21. Barter P.J., Caufield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122